Stephanie McLaughlin
Psychiatric/Mental Health · Madison, ALNPI 1508447939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.0% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Alkermes, Inc.$1K
- AbbVie$865
- Corium, LLC$742
- Otsuka America Pharmaceutical, Inc.$620
- Axsome Therapeutics, Inc.$474
- plus $3K from 20 others
What the payments were for
- Food & beverage$8,28699%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,180 |
| Alkermes, Inc. | 51 | $1,106 |
| AbbVie | 54 | $865 |
| Corium, LLC | 40 | $742 |
| Otsuka America Pharmaceutical, Inc. | 31 | $620 |
| Axsome Therapeutics, Inc. | 29 | $474 |
| Teva Pharmaceuticals USA, Inc. | 17 | $446 |
| Johnson & Johnson | 17 | $433 |
| Bausch Health US, LLC | 23 | $428 |
| Neurocrine Biosciences, Inc. | 15 | $418 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $369 |
| Almatica Pharma LLC | 15 | $318 |
| Lundbeck LLC | 8 | $154 |
| Neos Therapeutics, LP | 6 | $112 |
| Vanda Pharmaceuticals Inc. | 4 | $104 |
| Harmony Biosciences LLC | 3 | $103 |
| Supernus Pharmaceuticals, Inc. | 5 | $101 |
| Indivior Inc. | 3 | $92 |
| Idorsia Pharmaceuticals US Inc | 5 | $80 |
| Ironshore Pharmaceuticals Inc. | 3 | $64 |
| Tris Pharma Inc | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Avion Pharmaceuticals | 1 | $22 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
| Sage Therapeutics, LLC | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
How this compares
$8,398 in reported general payments places this provider in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 29 | $150,064 |
| VraylarCariprazine Hcl | 56 | $80,683 |
| LybalviOlanzapine/Samidorphan Malate | 25 | $42,335 |
| TrintellixVortioxetine Hydrobromide | 33 | $23,891 |
| Aripiprazole | 128 | $6,864 |
| Quetiapine Fumarate | 309 | $4,087 |
| Duloxetine Hcl | 121 | $3,593 |
| Oxcarbazepine | 83 | $2,802 |
| Haloperidol | 66 | $1,952 |
| Trazodone Hcl | 161 | $1,893 |
| Varenicline Tartrate | 13 | $1,833 |
| Risperidone | 160 | $1,692 |
| Buspirone Hcl | 109 | $1,649 |
| Fluoxetine Hcl | 180 | $1,616 |
| Bupropion XlBupropion Hcl | 103 | $1,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $446 | $150,06429 claims |
| AbbVieVraylar | $865 | $80,68356 claims |
| Alkermes, Inc.Lybalvi | $1,106 | $42,33525 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $369 | $23,89133 claims |
| Almatica Pharma LLCSertraline Hcl | $318 | $57094 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 378 psychiatric/mental health providers in Alabama.
Other psychiatric/mental health in Madison
- Keith WattsMadison$13K
- Michelle PrattMadison$13K
- Stephanie KitchenMadison$9K
- William CrainMadison$7K
- Lauren RossMadison$7K
- Angela WaldropMadison$6K
- Kelly GreerMadison$6K
- Laura GrahamMontgomery$80K
- Yuliya SpencerBirmingham$65K
- Keri BarrBay Minette$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.